D. Gancberg

发表

Gene and cell therapy funding opportunities in horizon 2020: an overview for 2014-2015.

R. Draghia‐Akli, D. Gancberg, 2014, Human gene therapy.

Quantitative determination of Roundup Ready soybean (Glycine max) extracted from highly processed flour

G. Berben, P. Corbisier, H. Emons, 2005, Analytical and bioanalytical chemistry.

HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice.

D. Larsimont, M. Piccart, F. Cardoso, 2002, Anticancer research.

Evaluation of Microtubule Associated Parameters (MTAPs) as predictive markers for Advanced Breast Cancer (ABC) patients treated with docetaxel

D. Larsimont, M. Piccart, F. Cardoso, 2001 .

Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study.

D. Larsimont, M. Piccart, F. Cardoso, 2002, Clinical breast cancer.

Reference materials (RMs) for analysis of the human factor II (prothrombin) gene G20210A mutation

P. Reitsma, M. Neumaier, P. Corbisier, 2005, Clinical chemistry and laboratory medicine.

In situ amplification of oestrogen receptor α mRNA in breast cancer cell lines and tumours

D. Larsimont, G. Leclercq, D. Gancberg, 2001 .

Trisomy 21 as the sole abnormality in a refractory anemia with ring sideroblasts.

A. Kentos, W. Feremans, D. Gancberg, 1999, Cancer genetics and cytogenetics.

Certification of reference materials for detection of the human prothrombin gene G20210A sequence variant

P. Corbisier, J. Márki-Zay, C. Mannhalter, 2008, Clinical chemistry and laboratory medicine.

Nucleic acid reference materials (NARMs): definitions and issues

C. Mamotte, R. V. van Schaik, M. Pazzagli, 2010, Clinical chemistry and laboratory medicine.

Considerations for the development of a reference method for sequencing of haploid DNA – an opinion paper on behalf of the IFCC Committee on Molecular Diagnostics. International Federation of Clinical Chemistry and Laboratory Medicine

Michael Neumaier, Alexandre Bureau, Mario Pazzagli, 2009, Clinical chemistry and laboratory medicine.

HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.

D. Larsimont, M. Piccart, J. Isola, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.

D. Larsimont, M. Piccart, J. Isola, 2000, The American journal of pathology.

Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma.

D. Larsimont, M. Piccart, J. Isola, 2002, Journal of clinical pathology.

Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes.

D. Larsimont, M. Piccart, F. Cardoso, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Trisomy 6 in Merkel cell carcinoma: a recurrent chromosomal aberration

D. Larsimont, J. Hamels, G. Rouas, 2000, Histopathology.

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites.

D. Larsimont, M. Piccart, F. Cardoso, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.

D. Larsimont, M. Piccart, J. Isola, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of HER-2/NEU Protein Expression in Breast Cancer by Immunohistochemistry: An Interlaboratory Study Assessing the Reproducibility of HER-2/NEU Testing

D. Larsimont, M. Piccart, J. Isola, 2002, Breast Cancer Research and Treatment.

Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel

D. Larsimont, M. Piccart, F. Cardoso, 2008, Clinical Cancer Research.

Tumor‐infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome

D. Larsimont, M. Piccart, G. Leclercq, 1999, International journal of cancer.

Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases.

D. Larsimont, M. Piccart, M. Paesmans, 2000, American journal of clinical pathology.

Oncoselective transduction of CD80 and CD86 in tumor cell lines using an autonomous recombinant parvovirus.

M. Moser, O. Leo, K. Thielemans, 2000, Anticancer Research.

A study of comparability in amplified fragment length polymorphism profiling using a simple model system

P. Corbisier, M. Burns, M. Holden, 2007, Electrophoresis.

The importance of international collaboration for rare diseases research: a European perspective

Christine M. Cutillo, C. Austin, A. Rath, 2017, Gene Therapy.

European external quality control study on the competence of laboratories to recognize rare sequence variants resulting in unusual genotyping results.

C. Klein, J. Márki-Zay, H. Schimmel, 2009, Clinical chemistry.

[Detection of extra chromosomes 12 by fluorescent in situ hybridization (FISH) in ovarian stromal tumors. Study of 12 cases and review of the literature].

D. Larsimont, J. Verdebout, D. Gancberg, 2001, Annales de pathologie.

Near haploid blast phase in a chronic myeloid leukemia detected by fluorescence in situ hybridization using a BCR-ABL probe.

C. Lohrisch, A. Kentos, W. Feremans, 2001, Cancer genetics and cytogenetics.